Biotech IPOs: Metsera and Maze Raise $415M, Signaling Investor …

In a sign of renewed investor confidence in the biotechnology sector, two companies, Metsera and Maze Therapeutics, raised a combined $415 million in initial public offerings (IPOs) this week. …

CouponFollow Extension

$415
OFF

Biotech IPOs: Metsera And Maze Raise $415M, Signaling Investor …

3 weeks from now

In a sign of renewed investor confidence in the biotechnology sector, two companies, Metsera and Maze Therapeutics, raised a combined $415 million in initial public offerings (IPOs) this week. …

ainvest.com

$275
OFF

Metsera’s IPO Raises $275M To Show How Its Obesity Drugs Can …

3 weeks from now

1 day ago · Maze boosted the deal size to $140 million by offering 8.75 million shares for $16 each. Combining its existing cash with the IPO proceeds, Maze plans to spend about $100 …

medcitynews.com

$415
OFF

Metsera And Maze IPOs Look To Bring $415M To Nasdaq

3 weeks from now

3 days ago · A week after the first IPO of the year was priced, obesity treatment developer Metsera Inc. and renal specialist Maze Therapeutics Inc. have begun trading on Nasdaq. …

bioworld.com

$275
OFF

Maze And Metsera Biotech IPOs To Begin Trading Friday

3 weeks from now

2 days ago · Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH Venture Partners and GV set to trade …

endpts.com

$415
OFF

4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined

3 weeks from now

2 days ago · New York-based Metsera Inc. sold nearly 15.3 million shares at $18 each, according to a statement, raising $275 million. Metsera's final IPO terms differ slightly from the original …

law360.com

$415
OFF

Maze Therapeutics, Inc. Common Stock (MAZE) - Yahoo Finance

3 weeks from now

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs. ... Metsera, Maze secure combined $415 million in IPOs. BioPharma Dive ...

yahoo.com

$415
OFF

Metsera, Maze Secure Combined $415 Million In IPOs

3 weeks from now

Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectiv...

biotech-now.co.uk

$415
OFF

MAZE - Maze Therapeutics Inc Stock Price And Quote - FINVIZ.com

3 weeks from now

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg) 07:30PM Maze Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire) …

finviz.com

$415
OFF

MTSR - Metsera Inc Stock Price And Quote - FINVIZ.com

3 weeks from now

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg) 06:53PM Metsera Announces Pricing of Initial Public Offering (GlobeNewswire) 02:57PM Metsera, …

finviz.com

$415
OFF

Top Gainers - Stock Screener - Snapshot - FINVIZ.com

3 weeks from now

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg) 06:53PM ... Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive) Metsera is a clinical …

finviz.com

$415
OFF

Metsera, Maze Secure Combined $415 Million In IPOs

3 weeks from now

4 days ago · The two offerings add to an uptick in IPO activity that some in the industry expect will continue throughout this year.Metsera and Maze Therapeutics are

ramaonhealthcare.com

$415
OFF

DRUGMAKERS METSERA AND MAZE RAISE COMBINED $415 …

3 weeks from now

3 days ago · DRUGMAKERS METSERA AND MAZE RAISE COMBINED $415 MILLION IN IPOS (Bloomberg) -- A pair of drugmakers priced their initial public offerings on Thursday, delivering …

eduenterprise.net

$415
OFF

MAZE THERAPEUTICS AKTIEN News | 5349 Nachrichten

3 weeks from now

3 days ago · Metsera, Maze Therapeutics secure combined $415 million in IPOs: 1: BioPharma Dive: Fr: Maze Therapeutics, Inc.: Maze Therapeutics Announces Pricing of Upsized Initial …

finanznachrichten.de

$4.79
OFF

Top 10 U.S. Biopharma Clusters 2021 - Genengnews.com

3 weeks from now

Mar 10, 2021 · San Diego fared best in VC (third with $4.794 billion in 2019 and 2020), helped by the $750 million Series B financing completed in November by La Jolla-based Resilience, a …

genengnews.com

FAQs about Biotech IPOs: Metsera and Maze Raise $415M, Signaling Investor … Coupon?

How much did Sana biotechnology raise?

Seattle-based Sana Biotechnology, whose treatments are based on its engineered cells, raised approximately $675.6 million in gross proceeds last month through an IPO, less than a year after completing a VC financing of more than $700 million. ...

What happened to IPOs in 2022?

IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt in 2022 as stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 24 drugmakers priced initial share sales. ...

Does Boston still have a top 10 biopharma cluster?

Boston and neighboring Cambridge, MA, anchor a regional biopharma cluster that remains the nation’s retains its top ranking in GEN’s top-10 list despite signs of growing strength from its closest competing regions. [National Resilience Inc. via Business Wire] ...

What's going on with Biopharma clusters in 2020?

Judging from the numbers reported by the nation’s top U.S. clusters, 2020 saw record-high amounts of lab space and NIH funding, as well as record-high numbers of jobs and patents. Those highs are reflected in high regional numbers seen in GEN’s annual ranking of the nation’s top 10 biopharma clusters. ...

Are biotechs receptive to IPOs?

For much of the past decade, biotechs found Wall Street receptive to their pitches. Public investment, drawn in by scientific advances and company successes, bolstered generations of new drugmakers. IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. ...